Invasight AG

Invasight is a Swiss-based pre early-clinical stage biotech start-up. Using our breakthrough technology, ACINDA™, we identify and design specific protein-protein interaction inhibitors (PPIs) for non-traditional intercellular protein targets, which cause cancer cell invasion. The most advanced of these first-in-class, protein-protein interaction inhibitors is F2i, a inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development. Our first-in-class PPIs combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers.